Construction at the Norton site is currently underway, with the new offerings anticipated to be operational by late 2027.

A key step to deliver RNAi therapeutics to diverse cell types and tissues beyond the liver from the collaboration of ...

Alnylam Pharmaceuticals faces near-term headwinds from TTR franchise momentum concerns. Click here to read why ALNY stock is ...

With six drugs approved for commercial development, Cambridge-based drugmaker Alnylam Pharmaceuticals Inc. is investing $250 ...

With demand for its RNA interference meds booming, Alnylam Pharmaceuticals has commenced work to soup up its flagship ...

RNAi therapeutics company Alnylam Pharmaceuticals has announced the planned expansion of its manufacturing facility in Norton ...

A technical analysis of Alnylam stock, explaining the recent correction, and what investors should expect next.

Fintel reports that on December 11, 2025, Stifel maintained coverage of Alnylam Pharmaceuticals (NasdaqGS:ALNY) with a Buy ...

Investors in Alnylam Pharmaceuticals, Inc. ALNY need to pay close attention to the stock based on moves in the options market ...

Detailed price information for Alnylam Pharmaceuticals (ALNY-Q) from The Globe and Mail including charting and trades.

Following a Wednesday morning event at Alnylam Pharmaceuticals on Commerce Way, Gov. Maura Healey spoke with The Sun ...

HELIOS-B is a global, randomized, double-blind, placebo-controlled clinical trial that evaluated the efficacy and safety of AMVUTTRA (R) in adult patients with wtATTR or hATTR amyloidosis with ...